Intermediate-term results of biventricular pacing in heart failure: Correlation between clinical and hemodynamic data

Citation
S. Reuter et al., Intermediate-term results of biventricular pacing in heart failure: Correlation between clinical and hemodynamic data, PACE, 23(11), 2000, pp. 1713-1717
Citations number
17
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
ISSN journal
01478389 → ACNP
Volume
23
Issue
11
Year of publication
2000
Part
2
Pages
1713 - 1717
Database
ISI
SICI code
0147-8389(200011)23:11<1713:IROBPI>2.0.ZU;2-1
Abstract
Biventricular (BV) pacing acutely improves the hemodynamic status of patien ts with chronic heart failure (CHF) and wide QRS complex. Long-term data ar e few. This study examined the relationship between hemodynamic and clinica l status of BV-paced CHF patients over an intermediate duration of follow-u p. Forty-seven patients (mean age 64 +/- 11 years, 19% women, LVEF 0.23 +/- 0.07) with QRS greater than or equal to 140 ms received a DDD-BVP device f or management of CHF due to ischemic disease in 22 (45%) patients. Clinical , electrocardiographic, exercise testing, and hemodynamic measurements were followed over an 8-month period. Seven patients died during the study, fou r patients suddenly. A significant decrease in NYHA class, from 3.3 +/- 0.6 before implantation, to 2.5 +/- 0.57 months after device implantation (P < 0.01) was measured, although 23% of patients reported no symptomatic impro vement. Paced QRS narrowing by BVP was unchanged throughout follow-up (166 +/- 28 vs 159 +/- 23 ms, P = NS). Maximal VO2 values did not change (15.7 /- 5 vs 16 +/- 8 mL/kg per min, P = NS). Echocardiographic parameters showe d that the degree of mitral regurgitation was significantly decreased durin g BV pacing compared with no pacing (1.8 +/- 1.0 before implantation vs 1.3 +/- 0.7, P < 0.01). The radionuclide LVEF wets not statistically different during no pacing, versus BV pacing at 3 months or 8 months after pacemaker implantation (24 +/- 9 vs 26 +/- 11 vs 25 +/- 10%, respectively, P = NS). Of nine patients whose QRS duration was prolonged by BV pacing, two were no t hemodynamically and clinically improved at the end of follow-up. Patients not improved by BV pacing had the same degree of QRS shortening (203 +/- 3 9 vs 167 +/- 26 ms, P < 0.01) as patients who were clinically improved duri ng follow-up (193 +/- 40 to 171 +/- 24 ms, P < 0.02). In multivariate analy sis, ischemic heart disease (P = 0.025), absence of mitral regurgitation re gression (P = 0.01), and older age (P = 0.04) predicted the absence of impr ovement by BV pacing. By standard noninvasive measures, intermediate-term B V pacing wets associated with no objective hemodynamic improvement, though more than three fourths of the patients reported being clinically improved. A global improvement in left ventricular function by BV pacing may become apparent only over longer periods of observations. Patients with CHF unimpr oved by BV pacing are more likely to suffer from ischemic heart disease and less likely to have BV pacing induced regression of mitral regurgitation, regardless of changes in QRS duration.